Cencora, Inc. $COR Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC increased its position in shares of Cencora, Inc. (NYSE:COR) by 1,750.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 319,546 shares of the company’s stock after buying an additional 302,281 shares during the quarter. SG Americas Securities LLC’s holdings in Cencora were worth $107,927,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of COR. United Bank grew its stake in Cencora by 4.5% in the 2nd quarter. United Bank now owns 7,032 shares of the company’s stock valued at $2,109,000 after acquiring an additional 305 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Cencora during the second quarter worth $329,000. Hillsdale Investment Management Inc. purchased a new position in Cencora during the second quarter valued at $768,000. MAI Capital Management lifted its holdings in Cencora by 2.9% during the second quarter. MAI Capital Management now owns 5,625 shares of the company’s stock valued at $1,687,000 after purchasing an additional 158 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in shares of Cencora by 42.7% in the second quarter. Franklin Resources Inc. now owns 309,659 shares of the company’s stock valued at $92,851,000 after purchasing an additional 92,685 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.38% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on COR. Morgan Stanley set a $380.00 price target on shares of Cencora in a research report on Tuesday, March 17th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Wells Fargo & Company increased their target price on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Finally, Bank of America lowered their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Twelve investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $403.17.

Cencora Price Performance

Shares of NYSE COR opened at $320.68 on Tuesday. The firm has a 50-day simple moving average of $354.50 and a 200-day simple moving average of $340.44. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The stock has a market capitalization of $62.38 billion, a price-to-earnings ratio of 38.54, a price-to-earnings-growth ratio of 1.52 and a beta of 0.68. Cencora, Inc. has a 52 week low of $265.59 and a 52 week high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same period in the previous year, the business posted $3.73 earnings per share. Cencora’s quarterly revenue was up 5.5% on a year-over-year basis. On average, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora agreed to buy the retina business of EyeSouth Partners for about $1.1 billion, expanding its Retina Consultants of America platform and adding specialized ophthalmology services that can drive higher-margin, recurring revenue and cross‑sell opportunities within its clinical and distribution businesses. Cencora to buy retina business of EyeSouth Partners for $1.1 billion — Reuters
• Neutral Sentiment: Cencora is included in actively managed ETF lineups (mentioned in a MarketBeat piece on active ETFs), which could modestly support demand from funds that favor active strategies but is unlikely to materially change near‑term fundamentals. Active ETFs Surge Past Passive, and These Are in the Lead — MarketBeat
• Neutral Sentiment: Multiple industry outlets and deal roundups covered the EyeSouth sale and other sector M&A activity — reinforcing that consolidation in specialty care remains active but not necessarily changing Cencora’s near‑term revenue guidance. Olympus Partners to sell EyeSouth’s retina business for $1.1b — PEHub
• Negative Sentiment: CFO retirement and a planned leadership change this summer raise questions about near‑term capital allocation and execution on growth plans; combined with the $1.1B deal, investors may be concerned about leverage and integration risk given Cencora’s relatively high debt levels. Cencora CFO Retirement Puts Capital Allocation And Growth Plans In Focus — Yahoo Finance

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.